Medical oxygen is critical for treating a wide range of health conditions and is recognized as an essential medicine by the WHO. Reflecting its therapeutic significance, in May 2023 the World Health Assembly unanimously adopted a resolution to enhance access to medical oxygen, emphasizing its role in strengthening health systems and achieving health-related SDGs.
Medical oxygen is necessary for treating low levels of oxygen of the blood, known as hypoxemia – which can result from various health conditions such as pneumonia, sepsis, trauma, and complications during childbirth. Hypoxemia is a major cause of mortality, especially among children under five and pregnant women.
Pneumonia accounts for approximately 8.5 million cases of hypoxemia in children under five annually in low- and middle-income countries (LMICs). Alarmingly, fewer than 20% of children hospitalized with severe pneumonia and hypoxemia receive the critical oxygen therapy they require.
Despite its importance, access to medical oxygen remains a challenge, particularly in LMICs, due to long-standing under-investment. Less than half of health facilities in sub-Saharan Africa have access to medical oxygen, and the average per capita consumption of oxygen in sub-Saharan Africa is ten times lower than in the US and EU. This significant gap underscores the challenge of meeting demand for oxygen in limited-resource settings.
Access to medical oxygen is hindered by numerous and complex barriers. Historically, the oxygen market has been characterized by low levels of innovation, with relatively few products introduced before the COVID-19 pandemic. Existing technologies have been plagued by operational challenges, including high levels of maintenance, significant power requirements, and logistical issues. These barriers have resulted in quality issues, particularly for unmaintained products, affordability challenges, as well as inconsistent supply and lagging adoption.
Maintaining the quality of respiratory care equipment is challenging due to the inapplicability of traditional quality assurance methods in many locations and a shortage of skilled professionals. This inconsistency in maintenance compromises oxygen purity, negatively impacting patient care.
Affordability is another major issue, particularly in low-income regions where the high cost of oxygen, especially liquid oxygen (LOX), is driven by significant infrastructure investments, market consolidation, and transportation expenses. These financial burdens restrict healthcare facilities’ ability to provide essential oxygen therapy.
Supply and delivery face significant challenges, especially in remote and low-resource settings. These areas often rely on inefficient oxygen cylinder exchanges due to inconsistent supply and the lack of medical gas piping systems. Additionally, obtaining spare parts can be problematic, leading to the underutilization of available oxygen resources.
The demand and adoption of oxygen-related products are constrained by operational issues such as maintenance and power requirements. While improved technologies exist, they are slow to reach the market, and pathways for adoption remain unclear, resulting in underutilized products and unmet demand.
Innovation in oxygen production and distribution technologies has been limited. Introducing new technologies with lower maintenance requirements could significantly enhance access, but the slow pace of innovation limits their availability.
Addressing these barriers is crucial to ensuring that healthcare facilities worldwide have the oxygen needed to provide quality care.
The COVID-19 pandemic underscored critical disparities in access to medical resources globally, revealing the pronounced discrepancies in oxygen availability between high-income countries and LMICs.
In response, the past four years have seen broad investment in medical oxygen. Since 2020, countries have rapidly introduced respiratory care equipment in large volumes to address the emergency, providing a much-needed response that goes far beyond COVID-19. Simultaneously, recognizing the gap in innovation, private industry, non-profits, and academic institutions have developed new products to address persistent design challenges.
Unitaid recently developed a medical oxygen innovation landscape that outlines a pipeline of emerging technologies and business models. Among the product areas that the landscape identifies as opportunities to fill critical gaps, are emerging large-scale oxygen production systems and medical gas piping systems. The landscape also recognizes pilot and potential business models capable of solving complex delivery challenges. Continued investment to build on the progress made in recent years is now needed to ensure that COVID-19 era investments and innovations are sustained, reach scale, and unlock broader access to oxygen.
Unitaid, having made considerable investments to improve access to oxygen, recognizes that sustained investment is required to catalyze ongoing product innovation and to evolve business models to provide consistent market access. Evidence suggests that enhancing oxygen production and delivery systems could reduce in-hospital mortality rates from childhood pneumonia by 50%, resulting in a cost-effectiveness proposition comparable to vaccination programs. With this significant potential for investment impact, Unitaid is launching a Call for Proposals focused on the following objectives:
- Facilitate introduction of novel oxygen technologies in LMICs: Assess and expand on recent innovations in large-capacity production and medical gas pipeline systems, which have limited uptake in LMICs, to better evaluate their feasibility and establish the most cost-effective use cases under real-world conditions.
- Expand access to oxygen solutions with new business models: Pilot and evaluate new business models, to sustain pandemic investments and optimize respiratory care equipment, including identifying channels for future uptake.